Dominik Dornbierer
Clinical Pharmacologist
Data updated
Papers
Trials
Research Footprint
Dominik Dornbierer appears in 11 tracked papers (2023–2026), most studied alongside Ayahuasca, DMT and Placebo, across Healthy Volunteers, Depressive Disorders and Medicinal Chemistry & Drug Development.
Most-cited paper: Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects (31 citations).
Frequent co-authors: Milan Scheidegger, Helena Aicher and Anne Aicher.
Publication Landscape
How the 11 papers Blossom tracks for Dominik Dornbierer line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Dominik Dornbierer's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 11 of 11 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Dominik Dornbierer publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Dominik Dornbierer publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Dominik A. Dornbierer is a clinical pharmacologist and researcher focused on the acute human pharmacology of psychedelic tryptamines and beta‑carbolines. His recent work centres on ayahuasca‑inspired formulations combining N,N‑dimethyltryptamine (DMT) with harmine, investigating dose–response relationships, pharmacokinetic–pharmacodynamic interactions and population PK‑PD modelling in healthy volunteer cohorts. Dornbierer has been involved in randomised controlled studies examining psychological outcomes such as mindfulness and compassion, experimental paradigms probing creativity during artistic creation, and neuroimaging work exploring self–other face differentiation under DMT/harmine influence.
He brings methodological expertise in factorial dose‑escalation designs, population pharmacokinetic and pharmacodynamic modelling, and multimodal outcome assessment (behavioural, psychometric and neuroimaging). Dornbierer’s contributions aim to characterise safety, acute subjective effects and mechanistic markers that can inform dose selection and translational development of serotoninergic psychedelic compounds for psychiatric research.
Key Impact
Notable for leading translational clinical research on co‑administered N,N‑dimethyltryptamine and harmine, integrating pharmacokinetics, pharmacodynamics, neuroimaging and behavioural outcomes.
Collaboration Network
13 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Dominik Dornbierer's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Dominik Dornbierer is associated with.